These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 17076986)

  • 41. A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
    Lucchi E; Minicuci N; Magnifico F; Mondini S; Calza A; Avanzi S; Villani D; Bellelli G; Trabucchi M
    Arch Gerontol Geriatr Suppl; 2004; (9):253-63. PubMed ID: 15207422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
    Reñé R; Ricart J; Hernández B;
    Neurologia; 2014 Mar; 29(2):86-93. PubMed ID: 23684446
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: a 21-month follow-up "real world" study.
    Calabria M; Geroldi C; Lussignoli G; Sabbatini F; Zanetti O
    Arch Gerontol Geriatr; 2009; 49(1):e6-11. PubMed ID: 18768226
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease.
    Vellas B; Cunha L; Gertz HJ; De Deyn PP; Wesnes K; Hammond G; Schwalen S;
    Curr Med Res Opin; 2005 Sep; 21(9):1423-9. PubMed ID: 16197661
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
    Jones RW; Kivipelto M; Feldman H; Sparks L; Doody R; Waters DD; Hey-Hadavi J; Breazna A; Schindler RJ; Ramos H;
    Alzheimers Dement; 2008 Mar; 4(2):145-53. PubMed ID: 18631958
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
    Campanozzi MD; Casali E; Neviani F; Martini E; Neri M
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():91-6. PubMed ID: 17317439
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.
    Wattmo C; Hansson O; Wallin AK; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2008; 26(3):203-11. PubMed ID: 18769065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholinesterase inhibitors in the treatment of dementia.
    Ellis JM
    J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease.
    Connelly PJ; Prentice NP; Fowler KG
    Int J Geriatr Psychiatry; 2005 Jul; 20(7):623-8. PubMed ID: 16021654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
    Freund-Levi Y; Basun H; Cederholm T; Faxén-Irving G; Garlind A; Grut M; Vedin I; Palmblad J; Wahlund LO; Eriksdotter-Jönhagen M
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention.
    Rosenblatt A; Samus QM; Onyike CU; Baker AS; McNabney M; Mayer LS; Brandt J; Lyketsos CG
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):178-84. PubMed ID: 17676652
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.
    Mahlberg R; Walther S; Eichmann U; Tracik F; Kunz D
    Arch Gerontol Geriatr; 2007; 45(1):19-26. PubMed ID: 16963137
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Verbal repetition in patients with Alzheimer's disease who receive donepezil.
    Asp E; Cloutier F; Fay S; Cook C; Robertson ML; Fisk J; Dei DW; Rockwood K
    Int J Geriatr Psychiatry; 2006 May; 21(5):426-31. PubMed ID: 16676290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A comparative study of the effectiveness and tolerability of a procedure involving slow dose-escalation of rivastigmine in patients with mild or moderate Alzheimer-type dementia: the SCALEX study].
    Agüera-Ortiz LF; Ramos-García M; Gobartt AL;
    Rev Neurol; 2008 May 1-15; 46(9):517-24. PubMed ID: 18446692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.
    Bilikiewicz A; Opala G; Podemski R; Puzyński S; Łapin J; Sołtys K; Ochudło S; Barcikowska M; Pfeffer A; Bilińska M; Paradowski B; Parnowski T; Gabryelewicz T
    Med Sci Monit; 2002 Feb; 8(2):PI9-15. PubMed ID: 11859291
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
    Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
    Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of nutritional status on the evolution of Alzheimer's disease and on response to acetylcholinesterase inhibitor treatment.
    Vellas B; Lauque S; Gillette-Guyonnet S; Andrieu S; Cortes F; Nourhashémi F; Cantet C; Ousset PJ; Grandjean H;
    J Nutr Health Aging; 2005; 9(2):75-80. PubMed ID: 15791349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment.
    Wattmo C; Wallin ÅK; Londos E; Minthon L
    Alzheimer Dis Assoc Disord; 2011; 25(1):63-72. PubMed ID: 20847636
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.
    Frankfort SV; Appels BA; De Boer A; Tulner LR; Van Campen JP; Koks CH; Beijnen JH
    Int J Clin Pract; 2006 Jun; 60(6):646-54. PubMed ID: 16805746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.